Loading...
•
Dec 31, 2024
Ardelyx Q4 2024 Earnings Report
Ardelyx reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.
Key Takeaways
Ardelyx enters 2025 in a position of strength, evidenced by significant year-over-year revenue growth for IBSRELA in 2024 and a strong first full year of XPHOZAH commercialization.
IBSRELA finished 2024 with $158.3 million in net product sales revenue, including $53.8 million in the fourth quarter, a 32% growth compared to the third quarter of 2024.
XPHOZAH recorded $160.9 million in net product sales revenue in its first full year of commercialization, including $57.2 million in the fourth quarter of 2024.
The company reaffirms combined peak sales of IBSRELA and XPHOZAH of $1.75 Billion.
The Company ended FY 2024 with $250.1 million in cash, cash equivalents and investments.
Forward Guidance
Ardelyx currently expects full year 2025 U.S. net product sales revenue for IBSRELA to be between $240 and $250 million.
Positive Outlook
- Ardelyx enters 2025 in a position of strength.
- Significant year-over-year revenue growth for IBSRELA in 2024.
- Strong first full year of XPHOZAH commercialization.
- Consistently high levels of commercial excellence.
- Meaningful long-term potential for existing commercial products.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...